Study Phase 3

A Randomized, Double-Blind, Parallel Group, Comparative Study of Flexibly Dosed Paliperidone Palmitate (25, 50, 75, or 100 mg eq.) Administered Every 4 Weeks and Flexibly Dosed RISPERDAL CONSTA (25, 37.5, or 50 mg) Administered Every 2 Weeks in Subjects With Schizophrenia

Trial Information

Generic NamePaliperidone palmitateProduct NameINVEGA SUSTENNA®Therapeutic AreaBehaviors and Mental DisordersEnrollment748% Female41%% White92%
Product ClassAtypical AntipsychoticsSponsor Protocol NumberR092670PSY3002Data PartnerJohnson & JohnsonCondition StudiedSchizophreniaMean/Median Age (Years)40.7

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.